

K972572

JAN 13 1998

## Section 2

### 510(k) Summary

Single Lumen Embolectomy Catheter  
American BioMed, Inc.  
The Woodlands, Texas 77380

**Section 2**  
**510(k) Premarket Notification Summary**

**July 1997**

Steven Rash  
President and CEO  
**American BioMed, Inc**  
P. O. Box 8429  
The Woodlands, Texas 77387-8429  
**(281) 367-3895**  
(281) 367-3212 Fax

---

<b>CLASSIFICATION NAME:</b>	Catheter, Embolectomy
<b>COMMON/USUAL NAME:</b>	Single Lumen Embolectomy Catheter
<b>PROPRIETARY NAME:</b>	Single Lumen Embolectomy Catheter
<b>CLASSIFICATION:</b>	21 CFR Part 870.5150 Catheter, Embolectomy
<b>PERFORMANCE STANDARDS:</b>	No Performance Standards for the Catheter, Embolectomy are effective as of this date.
<b>PREDICATED DEVICE</b>	Catheter Embolectomy K881455 and K905139, American BioMed, (CathLab Corp.) and Baxter Fogarty® Arterial Embolectomy Catheter.
<b>DEVICE DESCRIPTION</b>	Single Lumen Embolectomy catheter with three 100% silicone balloons. Catheter intended for use in removing arterial emboli. Sizes 2 to 7 French.
<b>INDICATIONS</b>	Removing arterial emboli.
<b>TECHNOLOGICAL CHARACTERISTICS</b>	This modification of K881455 and K905139, changes the number of balloons, two balloons are located at the distal end for embolus removal purpose, the third balloon is located at the proximal end as a safety balloon to prevent over injection of fluid.
<b>SUBSTANTIAL EQUIVALENCE</b>	The Single Lumen Embolectomy Catheter is equivalent to K881455, K905139, and Baxter

Section 2 page 1

July 1997

Fogarty Arterial Embolectomy Catheter, same intended use, with change in number of balloons.

# Statement of Similarities and Differences

Parameter	American BioMed Single Lumen Embolectomy Catheter	American BioMed Single Lumen Catheter K881455 & K905139	Baxter Fogarty Arterial Embolectomy Catheter K No. Not Found in FDA 510(k) Data Base
Body Material	Silicone Compound	Silicone Compound	Polyvinylchloride
Balloon Material	Silicone Compound	Silicone Compound	Latex
Balloon to Body Bonding	No. All Silicone. Formed through dipping process	No. All Silicone. Formed through dipping process	Yes
Number of Balloons	Three. Two at distal end and one at proximal end.	One. At distal end.	One. At distal end.
Catheter French Sizes	2, 3, 4, 5, 6, and 7	2, 3, 4, 5, 6, and 7	2, 3, 4, 5, 6, and 7
Catheter Length	40, 60, 80, 100 cm.	40, 60, 80, 100 cm.	40, 60, 80, 100 cm.
Inflated Balloon Diameter	2 Fr. - 4 mm 3 Fr. - 5 mm 4 Fr. - 9 mm 5 Fr. - 11 mm 6 Fr. - 13 mm 7 Fr. - 14 mm	2 Fr. - 4 mm 3 Fr. - 5 mm 4 Fr. - 9 mm 5 Fr. - 11 mm 6 Fr. - 13 mm 7 Fr. - 14 mm	2 Fr. - 4 mm 3 Fr. - 5 mm 4 Fr. - 9 mm 5 Fr. - 11 mm 6 Fr. - 13 mm 7 Fr. - 14 mm
Maximum Liquid Volume	2 Fr. - 0.05 ml 3 Fr. - 0.10 ml 4 Fr. - 0.50 ml 5 Fr. - 0.75 ml 6 Fr. - 1.25 ml 7 Fr. - 2.00 ml	2 Fr. - 0.05 ml 3 Fr. - 0.10 ml 4 Fr. - 0.50 ml 5 Fr. - 0.75 ml 6 Fr. - 1.25 ml 7 Fr. - 2.00 ml	2 Fr. - N/A 3 Fr. - 0.20 ml 4 Fr. - 0.75 ml 5 Fr. - 1.50 ml 6 Fr. - 2.00 ml 7 Fr. - 2.50 ml
Intended Use	Removing arterial emboli	Removing arterial emboli	Removing arterial emboli

## CONCLUSIONS

The conclusion drawn from the above is that the modified American BioMed Single lumen Embolectomy Catheters are equivalent in safety and efficacy to their predicate device.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

JAN 13 1998

American Biomed, Inc  
c/o J. Harvey Knauss  
Delphi Consulting Group  
11874 South Evelyn Circle  
Houston, Texas 77071

Re: K972572  
Single Lumen Embolectomy Catheter  
Regulatory Class: II (two)  
Product Code: DXE  
Dated: October 17, 1997  
Received: October 21, 1997

Dear Mr. Knauss:


We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink, reading "Thomas J. Callahan". The signature is fluid and cursive, with the first letters of the first and last names being capitalized and prominent.

Thomas J. Callahan, Ph.D.  
Director

Division of Cardiovascular, Respiratory,  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

510(k) Number (if Known)

Device Name: Single Lumen Embolectomy Catheter

Indications for use: Removing arterial emboli.

(PLEASE DO NOT WRITE BELOW THIS LINE- CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)


---

Prescription Use ☒  
(Per 21 CFR 801.109)

OR

Over-The-Counter Use ☐

(Optional Format 1-2-96)

  
\_\_\_\_\_  
(Division Sign-Off)

Division of Cardiovascular, Respiratory,  
and Neurological Devices

510(k) Number K972572